Advancing precision medicine in human epidermal growth factor receptor 2 negative gastric cancer: Insights from a novel nomogram for immunochemotherapy prognosis

Gastric cancer poses a significant global health burden, particularly in advanced human epidermal growth factor receptor 2-negative cases where prognosis remains poor despite advances in immunochemotherapy. The recent study by Yao et al introduces a nomogram model integrating programmed death ligand 1 expression, microsatellite status, tumor-node-metastasis stage, tumor differentiation, neutrophil-to-lymphocyte ratio, and C-reactive protein-albumin-lymphocyte index to predict progression-free and overall survival. This letter discusses the model's strengths, limitations, and its alignment with recent developments in biomarkers and therapies, emphasizing its potential for personalized medicine.